• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The 23-Valent Pneumoccocal (Pneumovax) Vaccine: For Which Patients?

Poll

For which of these patients would you give the 23-valent pneumoccocal vaccine?

Which of the following should get the 23-valent pneumoccocal (Pneumovax) vaccine per the Advisory Committee on Immunization Practices (ACIP) guidelines?

19-year-old who smokes a pack a day
16-year-old with diabetes mellitus
70-year-old who previously received a dose at age 64
All of the above
Related Videos
Infectious disease specialist talks about COVID-19 vaccine development
COVID 19 impact on healthcare provider mental health
Physician mental health expert discusses impact of COVID-19 on health care workers
Related Content
FDA Approves First New Antibiotic in Decades for Uncomplicated UTI in Women / image credit fda approval ©Walenmarus/stock.adobe.com

FDA Approves First New Antibiotic in Decades for Uncomplicated UTI

April 25th 2024
Article

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination / Image credit: ©Sherry Young/AdobeStock

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination

April 18th 2024
Article

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

Primary Viewpoints Episode 11: AAFP President-elect Discusses Greatest Concerns about Upcoming Flu Season

Primary Viewpoints Episode 11: AAFP President-elect Discusses Greatest Concerns about Upcoming Flu Season

September 13th 2021
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with incoming AAFP president Sterling Ransone, MD.

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine / image credit GSK vaccines: ©desertsands/stock.adobe.com

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA

April 17th 2024
Article

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research / image credit older man in hospital ©auremar/stock.adobe.com

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research

April 11th 2024
Article

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

© 2024 MJH Life Sciences

All rights reserved.